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The selective PPARc antagonist GW9662 reverses the protec-
tion of LPS in a model of renal ischemia-reperfusion.
Background. We have recently reported that pretreatment
of rats with endotoxin (lipopolysaccharide, LPS) and selec-
tive agonists of the nuclear receptor peroxisome proliferator-
activated receptor-c (PPARc) protect the kidney against
ischemia/reperfusion (I/R) injury. Here we investigate the hy-
pothesis that the renoprotective effects of LPS may be due to an
enhanced formation of endogenous ligands of PPARc, rather
than an up-regulation of PPARc expression.
Methods. Rats were pretreated with LPS (1 mg/kg, IP, 24
hours prior to ischemia) in the absence (control) or presence
of the selective PPARc antagonist GW9662 (1 mg/kg, IP, 24
and 12 hours prior to ischemia). Twenty-four hours after injec-
tion of LPS, rats were subjected to 60 minutes of bilateral renal
ischemia, followed by 6 hours of reperfusion. Serum and uri-
nary indicators of renal injury and dysfunction were measured,
specifically serum creatinine, aspartate aminotransferase, and
c-glutamyl-transferase, creatinine clearance, urine flow, and
fractional excretion of sodium. Kidney PPARc1 mRNA lev-
els were determined by reverse transcriptase-polymerase chain
reaction.
Results. Pretreatment with LPS significantly attenuated all
markers of renal injury and dysfunction caused by I/R. Most
notably, GW9662 abolished the protective effects of LPS. Addi-
tionally, I/R caused an up-regulation of kidney PPARc1 mRNA
levels compared to sham animals, which were unchanged in rats
pretreated with LPS.
Conclusion. We document here for the first time that endoge-
nous ligands of PPARc may contribute to the protection against
renal I/R injury afforded by LPS pretreatment in the rat.
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In hospitalized patients, ischemic acute tubular necro-
sis remains a significant medical problem and a major
cause of acute renal failure, with mortality rates remain-
ing unacceptably high, and has not improved in more than
50 years [1, 2]. Ischemia of the kidney is one of the most
common causes of acute renal failure, initiating a complex
and inter-related sequence of events resulting in injury to,
and the eventual death of, renal cells [3, 4]. This progno-
sis is complicated by the fact that reperfusion, although
essential for the survival of ischemic renal tissue, causes
additional damage (reperfusion injury) [5]. It is impor-
tant to understand which pathways play critical roles in
the determination of cell fate, since it is still relatively
unclear which signaling pathways can be modulated due
to cellular injury caused by conditions associated with
ischemia/reperfusion (I/R) [6, 7].
Peroxisome proliferator-activated receptors (PPARs)
are ligand-activated transcription factors belonging to the
nuclear receptor superfamily. PPARs bind to specific re-
sponse elements as heterodimers with the retinoid X re-
ceptor [8], and activate the transcription of target genes
in response to a variety of endogenous and exogenous
ligands [9]. Since the identification of the first PPAR
in the mouse [10], three isoforms—designated PPARa,
PPARb/d, and PPARc—have been cloned and character-
ized by their distinct expression patterns, different ligand-
binding specificity, and metabolic functions [11].
We have recently reported in this journal that pretreat-
ment of rats with a low, sublethal dose of lipopolysaccha-
ride (LPS, or endotoxin) substantially reduces the degree
of renal injury and dysfunction caused by 45 minutes of
ischemia and 6 hours of reperfusion [12]. We proposed
that the protective effects of LPS involve reduction of
the production of nitric oxide (NO) and peroxynitrite
subsequent to reduced P-selectin and inducible nitric
oxide synthase (iNOS) expression, and neutrophil re-
cruitment. However, the precise mechanism defining this
effect is still unknown. Since recent studies indicate that
PPARc is able to inhibit the expression of iNOS and
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adhesion molecules, induced by various agents [13–16],
we hypothesized that endogenous ligands of PPARc may
be generated, rather than an up-regulation of PPARc ex-
pression, by pretreatment of rats with LPS in sufficient
amounts to attenuate the renal injury and dysfunction
caused by I/R. To test this hypothesis, we investigated
whether the selective and irreversible PPARc antagonist
GW9662 [17] attenuates the reduction in renal injury and
dysfunction afforded by pretreatment of rats with LPS.
METHODS
Experimental protocol
Sixty-two male Wistar rats (Charles River, Ltd.,
Margate, UK) weighing 215 to 315 g were used in this
study. Rats received a standard diet and water ad libi-
tum, and were cared for in accordance with both the
UK Home Office Guidance in the Operation of the Ani-
mals (Scientific Procedures) Act 1986, published by Her
Majesty’s Stationery Office, London, UK, and the Guide
for the Care and Use of Laboratory Animals, published
by the American Physiological Society. Anesthetized rats
were subjected to bilateral renal ischemia for 60 minutes
followed by reperfusion for 6 hours. Animals were ran-
domly allocated into 6 groups as follows: (1) I/R group:
control, rats were administered 10% (v/v) DMSO (vehi-
cle for GW9662, 1 mL/kg, IP) 24 and 12 hours prior to
renal I/R, and saline (vehicle for LPS, 1 mL/kg, IP) 24
hours prior to renal I/R (N= 12); (2) I/R LPS group:
rats were administered 10% (v/v) DMSO (vehicle for
GW9662, 1 mL/kg, IP) 24 and 12 hours prior to renal I/R,
and LPS (1 mg/kg, IP) 24 hours prior to renal I/R (N= 11);
(3) I/R GW9662 group: rats were administered GW9662
(1 mg/kg, IP) 24 and 12 hours prior to renal I/R, and saline
(vehicle for LPS, 1 mL/kg, IP) 24 hours prior to renal I/R
(N= 9); (4) I/R LPS+GW9662 group: rats were admin-
istered GW9662 (1 mg/kg, IP) 24 and 12 hours prior to
renal I/R, and LPS (1 mg/kg, IP) 24 hours prior to re-
nal I/R (N= 11); (5) Sham group: rats were subjected to
the same surgical procedures as above, except for renal
I/R. Rats were administered 10% (v/v) DMSO (vehicle
for GW9662, 1 mL/kg, IP) and saline (vehicle for LPS,
1 mL/kg, IP) at times equivalent to those described above
(N= 12); (6) Sham GW9662 group: rats were subjected
to the same surgical procedures as above, except for renal
I/R. Rats were administered GW9662 (1 mg/kg, IP) and
saline (vehicle for LPS, 1 mL/kg, IP) at times equivalent
to those described above (N= 7).
The time and dose of LPS used were based on those
previously shown by our group to provide protection
against renal I/R injury in the rat [12]. The time and dose
of GW9662 used were chosen according to those previ-
ously shown to exert antagonism of PPARc [18, 19].
Animal surgery
All rats were anesthetized with sodium thiopentone
(Intraval sodium, 120 mg/kg IP; Merial Animal Health,
Ltd., Harlow, Essex, U.K.), and anesthesia was main-
tained by supplementary injections (∼10 mg/kg IV)
of sodium thiopentone. Anesthetized rats were placed
onto a thermostatically controlled heating mat (Harvard
Apparatus, Ltd., Kent, UK), and body temperature was
maintained at 38 ± 1◦C by means of a rectal probe at-
tached to a homeothermic blanket. A tracheotomy was
performed, and a small section of polyethylene tubing
was inserted into the airway (internal diameter 1.67 mm;
Portex, Kent, UK) to maintain airway patency and fa-
cilitate spontaneous respiration. The right carotid artery
was cannulated (internal diameter 0.58 mm; Portex), and
connected to a pressure transducer (Capto SP 844 Physi-
ological Pressure Transducer; AD Instruments, Hastings,
UK) for the measurement of mean arterial blood pres-
sure (MAP) and derivation of the heart rate (HR) from
the pulse waveform, which were displayed on a data
acquisition system (PowerLab 8e, Chart v4.04; AD In-
struments) installed on a IBM compatible personal com-
puter. MAP and HR were monitored for the duration of
each experiment. The jugular vein was cannulated (inter-
nal diameter 0.40 mm; Portex) for the administration of a
continuous infusion of saline. A midline laparotomy was
performed and the bladder was cannulated (internal di-
ameter 0.58 mm; Portex) for the collection of urine. The
kidneys were located inside the peritoneum, and the re-
nal pedicles, containing the renal artery, vein, and nerve
supplying each kidney, were carefully isolated.
Renal ischemia/reperfusion
Rats were subjected to bilateral renal occlusion for
60 minutes using nontraumatic artery clamps (Dieffen-
bach Bulldog Clamps; Harvard Apparatus Ltd.) to clamp
the renal pedicles, followed by reperfusion for 6 hours.
After the renal clamps were removed, the kidneys were
observed for a further 5 minutes to ensure reflow, af-
ter which 2 mL saline at 37◦C was injected into the
abdomen to ensure gut motility. Sham-operated rats un-
derwent identical surgical procedures to rats undergo-
ing I/R, except that artery clamps were not applied. All
groups described above received a continuous infusion of
0.9% (w/v) saline (2 mL/kg/h, IV) throughout the reper-
fusion period.
Measurement of biochemical parameters
At the end of the reperfusion period, 1 mL blood sam-
ples were collected via the carotid artery into S/1.3 tubes
containing serum gel (Sarstedt, Numbrecht, Germany),
after which the heart was removed to terminate the
experiment. The samples were centrifuged (6000g for
3 minutes) to separate serum from which biochemical
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parameters were measured within 24 hours (Vetlab Ser-
vices, Sussex, UK). Serum creatinine concentrations were
used as indicators of impaired renal (glomerular) func-
tion [20]. The rise in the serum levels of aspartate amino-
transferase (AST) and c-glutamyl transferase (c-GT) was
used as indicators of reperfusion-injury [21]. Urine sam-
ples were collected during the reperfusion period, and the
volume of urine produced recorded. Urinary creatinine
was measured and was used in conjunction with serum
creatinine concentration and urine flow to calculate cre-
atinine clearance using standard formulas that were used
as indicators of glomerular function [20]. Urinary Na+
was measured at the end of the repefusion period, and
used in conjunction with serum Na+ to estimate frac-
tional excretion of Na+ (FENa) using standard formulas,
and which was used as an indicator of tubular function
[22].
RNA extraction and reverse transcriptase-polymerase
chain reaction (RT-PCR)
Total RNA was isolated from renal samples in 2 mL of
TRIzol (Gibco BRL, Invitrogen Life Technologies, Invit-
rogen Corporation, Carlsbad, CA, USA). Two hundred
microliters of chloroform was added to the lysate, and the
mixture was centrifuged at 13,000 rpm for 5 minutes on a
tabletop centrifuge. The aqueous phase was transferred
to a fresh tube, and an equal volume of isopropanol was
added, mixed, and stored at −20◦C for 1 hour. After cen-
trifuging at 13,000 rpm for 20 minutes, the RNA pellet was
washed with 70% ethanol and left to dry prior to resus-
pending in diethylpyrocarbonate (DEPC)-treated water.
The amount of RNA was determined by spectrophotom-
etry, and the samples were stored at −80◦C.
First strand of cDNA was synthesized from 1 lg of to-
tal RNA, primed with oligo(dT)15 primer, and incubated
with AMV reverse transcriptase (Promega, Madison, WI,
USA), at 37◦C for 1 hour. Polymerase chain reaction
(PCR) amplification was performed using gene-specific
primer sequences—sense: 5′-CCTTTGGTGACTTTAT
GGAG-3′ and antisense: 5′-GGTGAAGGCTCATATC
TGTC-3′ for rat PPARc1. The amplification product was
predicted to be 324 bp in length. PCR amplification was
performed according to the following protocol: denatu-
ration, annealing, and elongation at 95, 50, and 72◦C for
30 seconds, 30 seconds, and 1 minute, respectively, for
30 cycles. Parallel amplification of rat glyceraldehyde-
3-phosphate-dehydrogenase (GAPDH) was performed
for reference using the following primer sequences—
sense: 5′-TGGAAAGCTGTGGCGTGATG-3′ and anti-
sense: 5′-TCCACCACCCTGTTGCTGTAGC-3′. PCR
products were electrophoresed on a 1.5% agarose gel
containing ethidium bromide and visualized by UV-
induced fluorescence. The density of each band was de-
termined using the Gelbase/Gelblot-Pro image analysis
software (Synoptics, Ltd., Cambridge, UK). The data are
presented as the ratio of the densitometric units of the
PPARc1 mRNA band to the densitometric units of the
GAPDH mRNA band.
Materials
Unless otherwise stated, all compounds used in this
study were purchased from Sigma-Aldrich Company,
Ltd. (Poole, Dorset, UK). All solutions used were pre-
pared using non-pyrogenic saline [0.9% (w/v) NaCl; Bax-
ter Healthcare, Ltd., Thetford, Norfolk, UK). LPS used
in this study was obtained from Escherichia coli serotype
0.127:B8 (Sigma). Thiopentone sodium (Intraval
sodium) was obtained from Rhone Merieux (Harlow, Es-
sex, UK). GW9662 was purchased from Alexis Biochem-
icals (Bingham, Nothingham, UK).
Statistical analysis
All values described in the text and figures are ex-
pressed as mean ± standard error of the mean (SEM) for
N observations. Each data point represents biochemical
measurements obtained from up to 12 separate animals.
One-way analysis of variance (ANOVA) with Dunnett’s
post-test was performed using GraphPad Prism version
4.02 for Windows (GraphPad Software, San Diego, CA,
USA, www.graphpad.com), and a P value of less than
0.05 was considered to be significant.
RESULTS
The mean ± SEM for the weights of the rats used in this
study was 259.4 ± 4 g, N = 62. On comparison with sham
animals, renal I/R produced significant increases in serum
and urinary markers of renal dysfunction and injury, as
described in detail below. Administration of GW9662 to
rats subjected to I/R did not result in any significant al-
teration in all the markers measured when compared to
control rats only (Figs. 1 to 4). Similarly, administration of
GW9662 to sham-operated rats had no significant effect
on all the markers measured when compared to sham-
operated rats only (Figs. 1 to 4).
Effect of the GW9662 on renal/glomerular dysfunction
caused by I/R in rats pretreated with LPS
Rats that underwent renal I/R exhibited a significant
increase in the serum level of creatinine compared with
sham-operated rats (Fig. 1A), suggesting a significant de-
gree of renal dysfunction. Compared to rats subjected
to I/R only (control), pretreatment of rats with LPS
(1 mg/kg, IP) 24 hours prior to renal I/R significantly
attenuated the increase in the serum level of creatinine
(Fig. 1A). The attenuation in serum creatinine obtained
after LPS pretreatment was reversed by administration
of the specific PPARc antagonist GW9662 (1 mg/kg, IP)
(Fig. 1A).
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Fig. 1. Effect of GW9662 on renal/glomerular dysfunction mediated
by I/R in rats pretreated with lipopolysaccharide. Serum creatinine lev-
els (A) and creatinine clearance (B) were measured subsequent to sham
operation (Sham, N = 12) or renal I/R (I/R, N = 12). Rats were ad-
ministered lipopolysaccharide [LPS (1 mg/kg, IP)] 24 hours prior to I/R
(I/R + LPS, N = 11) and/or GW9662 [GW (1 mg/kg, IP)] 24 and 12
hours prior to I/R (I/R + LPS + GW, N= 11; I/R + GW, N = 9). A
separate group of rats received GW9662 (1 mg/kg, IP) 24 and 12 hours
prior to sham operation (Sham + GW, N = 7). Data are expressed as
mean ± SEM for N number of observations. ∗P < 0.05 vs. I/R, •P <
0.05 vs. I/R + LPS.
In order to discount the possibility of a rapid increase
in serum creatinine levels due to increased release of
creatinine from muscle during I/R, creatinine clearance
was also measured (Fig. 1B). Rats subjected to renal
I/R demonstrated a significant attenuation in creatinine
clearance compared to sham-operated rats (Fig. 1B),
suggesting significant glomerular dysfunction. Compared
to rats subjected to I/R only, administration of LPS 24
hours prior to I/R produced a modest, but significant,
improvement in creatinine clearance. Most notably, this
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Fig. 2. Effect of GW9662 on tubular dysfunction subsequent to I/R in
rats pretreated with lipopolysaccharide. Alterations in fractional excre-
tion of Na+ (FENa) subsequent to sham operation (Sham, N = 12) or
renal I/R (I/R only, N = 12). Rats were administered lipopolysaccharide
[LPS (1 mg/kg, IP)] 24 hours prior to I/R (I/R + LPS, N = 11) and/or
GW9662 [GW (1 mg/kg, IP) 24 and 12 hours prior to I/R (I/R + LPS
+ GW, N= 11; I/R + GW, N = 9). A separate group of rats received
GW9662 (1 mg/kg, IP) 24 and 12 hours prior to sham operation (Sham
+ GW, N = 7). Data are expressed as mean ± SEM for N number of
observations. ∗P < 0.05 vs. I/R, •P < 0.05 vs. I/R + LPS.
preservation of creatinine clearance afforded by LPS pre-
treatment was abolished by GW9662 (Fig. 1B).
Effect of GW9662 on tubular dysfunction caused by I/R
in rats pretreated with LPS
Renal I/R produced a significant increase in FENa, sug-
gesting tubular dysfunction (Fig. 2). Pretreatment of rats
with LPS produced a significant attenuation in the I/R-
mediated increase in FENa, suggesting improvement in
tubular function (Fig. 2). Administration of GW9662 in
LPS-treated rats produced an increase in FENa, similar to
that measured in control rats (I/R only), thus abolishing
the protective effect mediated by LPS (Fig. 2).
Renal I/R caused a nonsignificant decrease in urine
flow compared with sham-operated rats (Fig. 3). How-
ever, rats subjected to renal I/R that received LPS pro-
duced a significantly greater volume of urine compared to
rats subjected to renal I/R alone (Fig. 3). Administration
of GW9662 to LPS-pretreated rats abolished this rise in
urine flow (Fig. 3).
Effect of GW9662 on reperfusion injury caused by I/R in
rats pretreated with LPS
Renal I/R produced a significant increase in the serum
concentrations of AST (Fig. 4A) and c-GT (Fig. 4B)
in comparison with levels obtained from sham-operated
rats. Serum concentrations of AST and c-GT, which were
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Fig. 3. Effect of GW9662 on urine flow subsequent to I/R in rats pre-
treated with lipopolysaccharide. Urine flow was measured subsequent
to sham operation (Sham, N = 12) or renal I/R (I/R only, N = 12).
Rats were administered lipopolysaccharide [LPS (1 mg/kg, IP)] 24 hours
prior to I/R (I/R + LPS, N = 11) and/or GW9662 [GW (1 mg/kg, IP)]
24 and 12 hours prior to I/R (I/R + LPS + GW, N= 11; I/R + GW,
N = 9). A separate group of rats received GW9662 (1 mg/kg, IP) 24
and 12 hours prior to sham operation (Sham + GW, N = 7). Data are
expressed as mean ± SEM for N number of observations. ∗P < 0.05 vs.
I/R, •P < 0.05 vs. I/R + LPS.
used as markers of reperfusion injury, were significantly
attenuated subsequent to administration of LPS (Figs. 4A
and B). Interestingly, GW9662 abolished the protective
effect afforded by LPS pretreatment (Figs. 4A and B).
Expression of PPARc1 mRNA in rat kidneys
To evaluate the expression of PPARc1 mRNA, we an-
alyzed the kidney by RT-PCR. Rats that underwent renal
I/R exhibited a significant increase in mRNA expression
of PPARc1 compared with sham-operated rats (Fig. 5).
Compared to rats subjected to I/R only (control), pre-
treatment of rats with LPS (1 mg/kg, IP) 24 hours prior
to renal I/R did not significantly change mRNA expres-
sion of PPARc1 in the rat kidney (Fig. 5).
DISCUSSION
Here we confirm that 24-hour pretreatment with a low
dose of LPS protects the kidney against renal dysfunction
and injury caused by bilateral occlusion (60 minutes) and
reperfusion (6 hours) in anesthetized rats. Specifically, in
rats subjected to renal I/R, LPS pretreatment attenuated
the (1) renal dysfunction (increase in serum creatinine);
(2) reperfusion-injury (increase in serum AST and cGT);
(3) glomerular dysfunction (decrease in creatinine clear-
ance); and (4) tubular dysfunction (increase in FENa).
These findings are in agreement with the notion that re-
nal I/R causes both renal and glomerular dysfunction [23].
This study demonstrates for the first time that the admin-
Sh
am
Sh
am
 + 
GW I/R
I/R
 + 
LP
S
I/R
 + 
GW
I/R
 + 
LP
S +
 GW
0.0
2.5
5.0
7.5
10.0
Se
ru
m
 γ-
G
T,
 IU
/L
B
Sh
am
Sh
am
 + 
GW I/R
I/R
 + 
LP
S
I/R
 + 
GW
I/R
 + 
LP
S +
 GW
0
500
1000
1500
2000
Se
ru
m
 A
ST
, I
U/
L
*
*
*
*
•
*
*
•
A
Fig. 4. Effect of GW9662 on reperfusion injury mediated by I/R in
rats pretreated with lipopolysaccharide. Serum concentrations of as-
partate aminotransferase (AST) (A) and c-glutamyl-transferase (c-GT)
(B) were measured subsequent to sham operation (Sham, N = 12) or
renal I/R (I/R, N = 12). Rats were administered lipopolysaccharide
[LPS (1 mg/kg, IP)] 24 hours prior to I/R (I/R + LPS, N = 11) and/or
GW9662 [GW (1 mg/kg, IP)] 24 and 12 hours prior to I/R (I/R + LPS
+ GW, N = 11; I/R + GW, N = 9). A separate group of rats received
GW9662 (1 mg/kg, IP) 24 and 12 hours prior to sham operation (Sham
+ GW, N = 7). Data are expressed as mean ± SEM for N number of
observations. ∗P < 0.05 vs. I/R, •P < 0.05 vs. I/R + LPS.
istration of a selective PPARc antagonist GW9662, 24
and 12 hours prior to I/R, abolishes the renoprotective
effects observed with pretreatment of LPS.
There have already been numerous studies document-
ing the protective effects of pretreating animals with
cell-wall fragments of either Gram-negative (LPS) or
Gram-positive (lipoteichoic acid, LTA) bacteria to re-
duce the degree of tissue injury caused by I/R in both
the heart [24, 25] and kidney [12] at 8 to 24 hours
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Fig. 5. RT-PCR analysis of PPARc1 and GAPDH expression in the
rat kidney. (Top) Gel photograph depicting representative PPARc1 and
GAPDH PCR products subsequent to sham operation (Sham) or renal
I/R (I/R). Rats were administered lipopolysaccharide [LPS (1 mg/kg,
IP)] 24 hours prior to I/R (I/R + LPS). (Bottom) Corresponding densit-
ometric analysis of PPARc1 PCR products from 3 different experiments
performed on different experimental days, represented as the PPARc1
mRNA percentage of GAPDH mRNA. Data are expressed as mean ±
SEM for N number of observations. ∗P < 0.05 vs. I/R.
after injection of small amounts (1 mg/kg) of LPS or LTA.
The mechanism(s) underlying these potent renoprotec-
tive effects of LPS (or LTA) are not clear. We report
here for the first time that the specific PPARc antagonist
GW9662 (1 mg/kg IP administered at the same time as,
and 12 hours after, LPS) largely attenuated the renopro-
tective effects of LPS in the rat. We also report here that
PPARc1 expression is up-regulated following I/R, which
is in keeping with previous studies [26]. This is not altered
following I/R in rats pretreated with LPS, suggesting that
the delayed renoprotective effects afforded by LPS in
the rat may be due to the overproduction of endogenous
PPARc agonists, such as lysophosphatidic acid (16:0 and
18:1), 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2), con-
jugated linoleic acid, azelaoyl-phosphocholine, and the
recently discovered nitrolinoleic acid [27], rather than an
overexpression of PPARc. The evidence that GW9662
alone did not worsen the injury and dysfunction in rats
subjected to I/R compared to rats subjected to I/R alone
suggests that (1) the level of injury sustained during I/R
may already be too high, or (2) pretreating with LPS
has the ability to increase the production of endogenous
PPARc ligands.
One could argue that GW9662 may have bound to
and interfered with the effects of LPS, as it was given
at the same time as LPS, and there is some evidence that
GW9662 can form covalent adducts with certain amino
acids. However, this is unlikely to explain the observed ef-
fects of GW9662 because GW9662 has only been demon-
strated to form covalent adducts with nucleophilic amino
acids, which are absent in the chemical structure of LPS
[17]. Furthermore, at the dose used in this study (1 mg/kg),
it has been previously demonstrated to interact selec-
tively with PPARc, acting as a potent and full PPARc
antagonist [19, 28]. In the absence of direct experimental
evidence, no conclusions can be reached with regard to
this suggestion.
Beneficial effects of PPARc agonists against I/R injury
have been documented in the intestine [29–31], lung [32],
heart [16, 33, 34], and kidney [35]. Although all 3 PPAR
subtypes have been identified in mammalian kidneys [36,
37], their role in renal physiology and pathophysiology
is just emerging. For instance, the expression of PPARc
is abundant in the renal inner medulla, where it is lo-
calized to the collecting duct and interstitial cells [36],
and endogenous PPARc activity is also associated with
the glomerular and medullary microvasculature [37], as
well as in the renal mesangium [38–40]. It has been re-
cently identified that there may be a relationship between
PPARc expression and renal I/R injury because several
hours after maximal PPARc expression, maximal renal
I/R injury was observed [26]. There is evidence that se-
lective PPARc agonists are of benefit in a number of renal
diseases, including diabetic glomerular disease, glomeru-
losclerosis, and the renal injury and dysfunction caused
by I/R [35, 41–45]. We have also previously demonstrated
that PPARc1 is expressed in the rat kidney, and that this
expression is maintained throughout renal I/R [35]. Fur-
thermore the PPARc agonists rosiglitazone and ciglita-
zone reduced the development of glomerular and tubular
dysfunction caused by I/R without affecting PPARc1 ex-
pression [35]. In the experiments reported here, we con-
firmed by RT-PCR not only that PPARc1 is expressed in
the rat kidney, but that its expression is increased follow-
ing I/R.
Surprisingly, there is less information about the role
of endogenous ligands for PPARc in health and dis-
ease. Nakajima et al observed that heterozygous PPARc-
deficient mice subjected to intestinal I/R suffered more
pronounced injury than wild-type control mice, thus sug-
gesting a protective role for endogenous PPARc activity
in I/R-mediated injury [29]. Similarly, the existence of
an endogenous protective pathway mediated by PPARc
activation has been recently demonstrated in a model
of gastric I/R injury with the use of PPARc-deficient
mice [46]. To confirm the protective role of endogenous
PPARc agonists, we have previously reported that 15d-
PGJ2 [47] significantly reduces renal dysfunction and in-
jury caused by I/R of the kidney [22], as well as the tissue
injury caused by I/R of the gut [48], hemorrhagic shock
[18], septic shock [28], colitis [49], and inflammation [50].
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We have previously demonstrated that one possible
mechanism by which PPARc activation mediated by
endogenous or exogenous ligands leads to protection
against renal I/R injury and dysfunction is through the
reduction of oxidative stress and the inflammatory re-
sponse [22, 35]. We also reported that LPS pretreatment
ameliorates I/R injury of the kidney via the inhibition of
the same pathways [12]. Taken together, these findings
and the results reported here strongly suggest that the
observed protective effect of pretreating with LPS in the
rat kidney exposed to I/R likely relates to the activation of
PPARc mediated by endogenous ligands, which leads to
decreased oxidative stress and inflammation. This notion,
which is only now beginning to be elucidated, is in keep-
ing with the work of Leininger et al, who demonstrated
that the activation of PPARc coincided with, or closely
followed, an endotoxin challenge in peripheral porcine
blood monocytes [51]. Furthermore, this agrees with the
study of Von Knethen et al, who observed that LPS pro-
moted desensitization of macrophages through PPARc
activation, probably inducing the production of activating
ligands, such as 15d-PGJ2 [52]. Therefore, we could spec-
ulate that levels of 15d-PGJ2 may be reduced in patients
suffering ischemic acute renal failure, and that pretreating
with LPS may protect the kidney against the renal injury
and dysfunction by not only stimulating PPARc activa-
tion, but also enhancing the endogenous production of
PPARc ligands. Although this warrants further investiga-
tion, it would correlate well with the observation that the
levels of the 15d-PGJ2 precursor, PGJ2, are reduced in
mice suffering from immune complex glomerulonephri-
tis [53], and that 15d-PGJ2 contributes to the resolution
of renal I/R injury and dysfunction [22].
CONCLUSION
This paper demonstrates for the first time that the de-
layed renoprotective effects of LPS are in part due to
the generation of endogenous PPARc ligands, and not
due to an overexpression of PPARc. However, further
investigation is still required to determine the source and
likely candidate for the PPARc ligand(s). The use of se-
lective and irreversible PPARc antagonists may represent
a novel and interesting pharmacologic approach to inves-
tigate the role of endogenous PPARc ligands in various
pathophysiologic conditions.
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